Hood River Capital Management LLC Has $85.99 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hood River Capital Management LLC cut its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,070,980 shares of the medical equipment provider’s stock after selling 51,085 shares during the period. Lantheus makes up approximately 1.8% of Hood River Capital Management LLC’s portfolio, making the stock its 12th biggest position. Hood River Capital Management LLC owned approximately 1.55% of Lantheus worth $85,989,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Daiwa Securities Group Inc. bought a new stake in Lantheus in the first quarter valued at $1,269,000. Nordea Investment Management AB increased its position in Lantheus by 42.6% in the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after buying an additional 14,147 shares in the last quarter. Hancock Whitney Corp raised its stake in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after buying an additional 14,639 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Lantheus in the second quarter worth approximately $290,000. Finally, Pitcairn Co. grew its stake in Lantheus by 117.0% in the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after acquiring an additional 4,509 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares in the company, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,852 shares of company stock valued at $3,922,001. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of research reports. Leerink Partners upped their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley upped their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. JMP Securities decreased their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Finally, Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Stock Up 1.4 %

Shares of NASDAQ:LNTH opened at $110.05 on Monday. The firm has a fifty day moving average of $105.51 and a 200 day moving average of $84.39. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The firm has a market capitalization of $7.63 billion, a PE ratio of 16.80 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.40 earnings per share. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.